Novo Nordisk is paying $240 million up front for global rights to zaltenibart, an Omeros drug that blocks the MASP-3 protein to treat diseases caused by excessive activity of the complement system.

BC Ferries remains indispensable, but it cannot and should not be the only player shaping the future of coastal mobility.

Omeros Corporation (NASDAQ: OMER) is one of the Reddit stocks that will go to the moon. On October 15, Omeros Corporation and ...

Neil Bressler, M.D., a professor of ophthalmology at Johns Hopkins and editor-in-chief of JAMA Ophthalmology, argued that complement inhibition for geographic atrophy is a game changer. His debating ...

What if every team in the NFL had to be active to make a move at the NFL trade deadline in 2025? Here would be the ideal ...

With the federal shutdown entering its fourth week, spurred by a stalemate over the cost of health insurance for 22 million ...

Omeros' stock surged over 150% after licensing zaltenibart to Novo Nordisk for $240M upfront, plus milestones and royalties.

The residential battery energy storage system is the first non-vehicle product by Ola Electric. This new solution will ...

Learn about the innovative plug flow technology that could make rain a major renewable energy source for cities worldwide.

This means upgrading coal-fired power plants for cleaner and more flexible operation. It means extending the EV charging ...

The City of Hazleton is launching a new camera system they say will increase safety in the city and complement the existing ...

India’s new envoy to Canada rejected Foreign Minister Anita Anand’s claim that New Delhi has agreed to restore Canada’s full ...